title: Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A.
abstract: Objective To evaluate the extended follow-up of the CYCLOFA-LUNE trial, a randomized prospective trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide (CPH) or cyclosporine A (CyA). Patients and methods Data for kidney function and adverse events were collected by a cross-sectional survey for 38 of 40 patients initially randomized in the CYCLOFA-LUNE trial. Results The median follow-up time was 7.7 years (range 5.0-10.3). Rates of renal impairment and end-stage renal disease, adverse events (death, cardiovascular event, tumor, premature menopause) did not differ between the CPH and CyA group, nor did mean serum creatinine, 24 h proteinuria and SLICC damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs. Conclusion An immunosuppressive regimen based on CyA achieved similar clinical results to that based on CPH in the very long term.
authors.affiliation: 1Institute of Rheumatology and First Faculty of Medicine, Charles University in Prague, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Závada
authors.forename: S
authors.initials: S
authors.lastname: Sinikka Pesicková
authors.forename: R
authors.initials: R
authors.lastname: Rysavá
authors.forename: P
authors.initials: P
authors.lastname: Horák
authors.forename: Z
authors.initials: Z
authors.lastname: Hrncír
authors.forename: J
authors.initials: J
authors.lastname: Lukác
authors.forename: J
authors.initials: J
authors.lastname: Rovensky
authors.forename: J
authors.initials: J
authors.lastname: Vítová
authors.forename: M
authors.initials: M
authors.lastname: Havrda
authors.forename: I
authors.initials: I
authors.lastname: Rychlík
authors.forename: J
authors.initials: J
authors.lastname: Böhmova
authors.forename: V
authors.initials: V
authors.lastname: Vlasáková
authors.forename: J
authors.initials: J
authors.lastname: Slatinská
authors.forename: J
authors.initials: J
authors.lastname: Zadrazil
authors.forename: M
authors.initials: M
authors.lastname: Olejárová
authors.forename: D
authors.initials: D
authors.lastname: Tegzova
authors.forename: V
authors.initials: V
authors.lastname: Tesar
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D003520:Cyclophosphamide / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D051437:Renal Insufficiency / Q000139:chemically induced / Q000473:pathology
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide
keywords: Lupus nephritis; cyclosporine A; systemic lupus erythematosus; treatment